| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002780027 |
| P356 | DOI | 10.1038/CLPT.2009.291 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/clpt.2009.291 |
| P932 | PMC publication ID | 2928561 |
| P698 | PubMed publication ID | 20200517 |
| P5875 | ResearchGate publication ID | 41722325 |
| P50 | author | Paul Ridker | Q7153226 |
| P2093 | author name string | H L McLeod | |
| C R King | |||
| R D Miller | |||
| S R Patel | |||
| B F Gage | |||
| C S Eby | |||
| E Deych | |||
| P E Milligan | |||
| L H Cavallari | |||
| G R Grice | |||
| R Porche-Sorbet | |||
| D Voora | |||
| D C Koboldt | |||
| M Crankshaw | |||
| P A Lenzini | |||
| P2860 | cites work | Hereditary warfarin resistance. | Q40728534 |
| Efficient high-throughput resequencing of genomic DNA. | Q40949185 | ||
| A molecular mechanism for genetic warfarin resistance in the rat. | Q43771296 | ||
| A genome-wide association study of acenocoumarol maintenance dosage. | Q45939541 | ||
| Pyrosequencing of clinically relevant polymorphisms | Q46650502 | ||
| Factors influencing warfarin dose requirements in African-Americans | Q46885448 | ||
| Two-stage designs for gene-disease association studies with sample size constraints | Q47408883 | ||
| Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. | Q51975669 | ||
| The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. | Q53233863 | ||
| Pyrosequencing: a simple method for accurate genotyping. | Q54565756 | ||
| Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians | Q61850138 | ||
| Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population | Q79451353 | ||
| Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin | Q82627288 | ||
| Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol | Q22337068 | ||
| WGAViewer: software for genomic annotation of whole genome association studies | Q24646837 | ||
| Haploview: analysis and visualization of LD and haplotype maps | Q27860955 | ||
| Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal | Q28195525 | ||
| The vitamin K-dependent carboxylase | Q28207074 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Molecular cloning of a cDNA encoding human calumenin, expression in Escherichia coli and analysis of its Ca2+-binding activity | Q28277384 | ||
| A sequencing method based on real-time pyrophosphate | Q28279786 | ||
| A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose | Q28475004 | ||
| The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats | Q28576911 | ||
| Relative impact of nucleotide and copy number variation on gene expression phenotypes | Q29614883 | ||
| Population genomics of human gene expression | Q29614905 | ||
| Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. | Q34061511 | ||
| Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
| Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. | Q34385127 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization | Q34519498 | ||
| CYP4F2 genetic variant alters required warfarin dose | Q34746151 | ||
| Association of warfarin dose with genes involved in its action and metabolism | Q35633802 | ||
| siRNA silencing of calumenin enhances functional factor IX production | Q35848852 | ||
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose | Q36835176 | ||
| Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection | Q36914625 | ||
| VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans | Q36982736 | ||
| The largest prospective warfarin-treated cohort supports genetic forecasting | Q37071087 | ||
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin | Q37196787 | ||
| Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. | Q37216750 | ||
| Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans | Q37376879 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 445-451 | |
| P577 | publication date | 2010-03-03 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans | |
| P478 | volume | 87 |
| Q34050936 | A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients |
| Q37908891 | A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? |
| Q39053849 | Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach |
| Q87307841 | Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population |
| Q87186109 | CALibrating the CALumenin gene: New insights in overcoming the vascular CALcification CALamity? |
| Q21563496 | Chapter 7: Pharmacogenomics |
| Q37606335 | Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement |
| Q26823542 | Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? |
| Q35795982 | Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU |
| Q36954725 | Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements? |
| Q89619881 | Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting |
| Q93000621 | Effects of Natural Progesterone and Synthetic Progestin on Germ Layer Gene Expression in a Human Embryoid Body Model |
| Q50849656 | Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats. |
| Q33591111 | Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans |
| Q42245258 | Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity |
| Q35687799 | Fibulin-1C, C1 Esterase Inhibitor and Glucose Regulated Protein 75 Interact with the CREC Proteins, Calumenin and Reticulocalbin |
| Q49811574 | Gamma-glutamyl carboxylase and its influence on warfarin dose. |
| Q34571746 | Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients |
| Q43113299 | Genetic determinants of variability in warfarin response after the dose-titration phase. |
| Q31016306 | Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians |
| Q34284362 | Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. |
| Q37138272 | Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study |
| Q45827969 | Genetics of warfarin dosing--one polymorphism at a time |
| Q38321269 | Genotype-guided coumarin dosing: where are we now and where do we need to go next? |
| Q37806660 | Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel |
| Q47982335 | Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans |
| Q57749449 | Letter to the Editor: Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians |
| Q36630081 | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium |
| Q38078754 | Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms |
| Q37828165 | Pharmacoeconomic evaluation of warfarin pharmacogenomics. |
| Q55717925 | Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. |
| Q57805160 | Pharmacogenetics of warfarin dosing in patients of African and European ancestry |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q36629209 | Pharmacogenomics of warfarin in populations of African descent |
| Q35309161 | Pharmacogenomics: application to the management of cardiovascular disease |
| Q34791041 | Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. |
| Q35219658 | Population diversity and the performance of warfarin dosing algorithms |
| Q35991881 | Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record |
| Q35884265 | Race influences warfarin dose changes associated with genetic factors. |
| Q36717256 | Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users |
| Q36848449 | Role of pharmacogenomics in the management of traditional and novel oral anticoagulants |
| Q38103055 | Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1. |
| Q36228428 | The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review |
| Q36294461 | The future of warfarin pharmacogenetics in under-represented minority groups |
| Q44498037 | The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. |
| Q38496232 | Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice |
| Q47345423 | VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. |
| Q38983845 | Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. |
| Q38696567 | Warfarin Pharmacogenomics in Diverse Populations. |
| Q51337900 | Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. |
| Q27027304 | Warfarin pharmacogenetics: does more accurate dosing benefit patients? |
Search more.